The US may use “trade tools” to retaliate against European ESG regulations that affect American companies, said Howard ...

ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Guggenheim in a research report issued to clients and investors on Monday,Benzinga reports.

Equities research analysts at Cantor Fitzgerald decreased their FY2025 EPS estimates for Kimball Electronics in a research note issued on Thursday, February 6th. Cantor Fitzgerald analyst D. Soderberg ...

Fintel reports that on February 11, 2025, Cantor Fitzgerald initiated coverage of Domo (NasdaqGM:DOMO) with a Overweight ...

Cantor Fitzgerald came out and expressed concerns around the Magnificent Seven group, saying the stocks are “vulnerable.” ...

Cantor Fitzgerald reaffirmed its Overweight rating and $170.00 price target on Ascendis Pharma (NASDAQ:ASND) shares, currently trading at $119.49. The firm's analyst highlighted the early adoption of ...

Will the Senate GOP confirm controversial picks like Tulsi Gabbard and RFK Jr.? Here’s the hearings schedule and list of ...

President Trump pumped the brakes last week on a pledge to shut down an import tax exemption for cheap consumer goods from ...

Cantor Fitzgerald analyst Deepak Mathivanan maintained a Buy rating on Pinterest (PINS – Research Report) today and set a price target of ...

It’s not that the Trump administration is anti-Goldman Sachs, sources say, but rather there just isn’t as much talent to take ...